<DOC>
	<DOCNO>NCT01910389</DOCNO>
	<brief_summary>This study multi-center , prospective , randomize , double blind , placebo-controlled clinical trial . Subjects study adults New York Heart Association ( NYHA ) Class II-IV heart failure ( HF ) due leave ventricular systolic dysfunction ( LVSD ) , leave ventricular ejection fraction ( LVEF ) &lt; 0.40 , secondary pulmonary hypertension ( PH ) . The purpose study evaluate safety , effectiveness , effect tadalafil compare placebo subject ' functional capacity / quality life .</brief_summary>
	<brief_title>Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Tadalafil</mesh_term>
	<criteria>Male female age 21 year old . NYHA Class IIIV HF LVSD ( recent LVEF &lt; 0.40 ) . At high risk future clinical instability , indicate EITHER : hospitalization primary reason decompensated HF within 12 month prior screen ; OR plasma Btype Natriuretic Peptide ( BNP ) level ≥ 300 pg/ml Nterminal prohormone brain natriuretic peptide ( NTproBNP ) ≥1800pg/ml measure period clinical stability 3 month prior screen . Documented secondary PH within last 6 month Medication device treatment accord current American Heart Association/American College Cardiology ( AHA/ACC ) guideline . Stable medical therapy 30 day prior randomization AfricanAmerican patient intolerant otherwise unable unwilling utilize isosorbide dinitrate/hydralazine therapy include . Willingness comply protocol , attend followup appointment , complete study assessment provide write informed consent . Concurrent anticipate nitrate use reason , nitrate use within 14 day prior screen day randomization . Known allergy , hypersensitivity ( anaphylaxis ) , adverse reaction tadalafil Phosphodiesterase Type 5 ( PDE5 ) inhibitor Erectile dysfunction treat PDE5 inhibitor . Severe renal dysfunction define estimate glomerular filtration rate ( GFR ) &lt; 30 ml/min/1.73 m^2 require chronic dialysis Current use alpha antagonist ( except carvedilol tamsulosin ) use cytochrome P450 3A4 inhibitor ( ketoconazole , itraconazole , erythromycin , cimetidine ) . Patients used protease inhibitor P450 3A4 inhibitor longer one week enrol . Pulmonary arterial hypertension ( World Health Organization ( WHO ) Group I , IIIV ) PDE5 inhibitor therapy may indicate Severe pulmonary disease require home oxygen therapy Comorbidities include clinically significant valvular stenosis ( aortic valve area &lt; 0.8 cm^2 mitral valve area &lt; 1.0 cm^2 ) , uncontrolled hypertension ( systolic blood pressure ≥180 mmHg diastolic blood pressure ≥100 mmHg ) hypotension ( systolic blood pressure &lt; 85 mmHg ) Chronic intravenous inotrope therapy Nonarteritic anterior ischemic optic neuropathy ( NAION ) ST elevation MI ( STEMI ) within 90 day prior screen Coronary Artery Bypass Grafting ( CABG ) mitral valve surgery , initiation cardiac resynchronization ( CRT ) initiation βblocker therapy within 6 month prior screen Infiltrative inflammatory myocardial disease ( e.g . amyloid , sarcoid ) Heart transplant recipient United Network Organ Sharing ( UNOS ) status 1A 1B Mechanical circulatory support ( MCS ) use plan MCS use time consent Active malignancy ( except nonmelanoma skin cancer ) require therapy observation . Severe noncardiac illness result life expectancy judge less three year Known chronic hepatic disease define aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) level &gt; 3.0 time upper limit normal Inability walk even step due noncardiac ( e.g . orthopedic ) reason Participation clinical trial within last 30 day ( exception observational study ) Previous randomization PITCHHF</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>tadalafil</keyword>
	<keyword>Phosphodiesterase Type 5 Inhibition</keyword>
</DOC>